Novel device-based therapies to improve outcome in ST-segment elevation myocardial infarction

Area of Science:

• Cardiology
• Interventional Cardiology
• Biomedical Engineering

Background:

• Primary percutaneous coronary intervention (PPCI) has improved ST-elevation myocardial infarction (STEMI) outcomes, but prognosis remains suboptimal.
• Significant rates of heart failure, cardiogenic shock, and death persist despite technically successful PPCI.
• Suboptimal myocardial reperfusion, large infarct size, and coronary microvascular injury contribute to poor long-term prognosis in STEMI survivors.

Purpose of the Study:

• To review novel device-based therapies for STEMI.
• To discuss technologies targeting distal embolization, ischemia/reperfusion injury, and microvascular function.
• To critically evaluate the evidence and future clinical implementation of these novel STEMI treatments.

Main Methods:

• Literature review of device-based therapies for STEMI.
• Categorization of therapies based on targeted pathophysiological pathways.
• Analysis of pathophysiological background, procedural details, and available evidence.

Main Results:

• Several device-based therapies are emerging to address suboptimal reperfusion in STEMI.
• Technologies focus on preventing atherothrombotic embolization, mitigating ischemia/reperfusion injury, and enhancing microvascular function.
• Evidence for these novel therapies varies, requiring further critical evaluation.

Conclusions:

• Device-based therapies represent a promising approach to improve STEMI patient outcomes beyond current PPCI.
• Targeting microvascular injury and distal embolization is crucial for enhancing myocardial reperfusion.
• Further research and clinical trials are needed to establish the role of these technologies in routine STEMI care.